Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 12Unknown 2Terminated 2Withdrawn 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 4Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Inflammatory Breast Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 27Taxes 9Capecitabine 8Albumin-Bound Paclitaxel 6pembrolizumab 5Radiosurgery 5Oxaliplatin 5Bevacizumab 5130-nm albumin-bound paclitaxel 5Surgical Procedures, Operative 4Specimen Handling 4Secretin 4Fluorouracil 4Drug Therapy 4Ascorbic Acid 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Irinotecan 3Cyclophosphamide 3Cisplatin 3Biopsy 3palbociclib 2methylnaltrexone 2folfirinox 2fludarabine 2entinostat 2aldesleukin 2Trastuzumab 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Pancreatic Neoplasms × Neoadjuvant Therapy × Clear all
NCT00524069 2013-02-01

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Roswell Park Cancer Institute

Phase NA Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡